{"title":"缓释罂粟碱和普通罂粟碱的人体吸收。","authors":"J Kanto, E Iisalo, D Manell, R Mäntylä","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The concentrations of papaverine in the plasma of healthy volunteers were determined by a GLC-method both after single and repeated oral doses of plain and sustained-release drug formulation. In both experiments the AUC-value after the sustained-release drug form was significantly lower than after the plain papaverine and no maintenance of plasma levels for 12 hours after the sustained-release drug form was observed. Our work demonstrates that the systemic availability or papaverine can be markedly affected by product formulation.</p>","PeriodicalId":75937,"journal":{"name":"International journal of clinical pharmacology and biopharmacy","volume":"17 9","pages":"375-7"},"PeriodicalIF":0.0000,"publicationDate":"1979-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Absorption of sustained-release and plain papaverine in man.\",\"authors\":\"J Kanto, E Iisalo, D Manell, R Mäntylä\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The concentrations of papaverine in the plasma of healthy volunteers were determined by a GLC-method both after single and repeated oral doses of plain and sustained-release drug formulation. In both experiments the AUC-value after the sustained-release drug form was significantly lower than after the plain papaverine and no maintenance of plasma levels for 12 hours after the sustained-release drug form was observed. Our work demonstrates that the systemic availability or papaverine can be markedly affected by product formulation.</p>\",\"PeriodicalId\":75937,\"journal\":{\"name\":\"International journal of clinical pharmacology and biopharmacy\",\"volume\":\"17 9\",\"pages\":\"375-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1979-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of clinical pharmacology and biopharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical pharmacology and biopharmacy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Absorption of sustained-release and plain papaverine in man.
The concentrations of papaverine in the plasma of healthy volunteers were determined by a GLC-method both after single and repeated oral doses of plain and sustained-release drug formulation. In both experiments the AUC-value after the sustained-release drug form was significantly lower than after the plain papaverine and no maintenance of plasma levels for 12 hours after the sustained-release drug form was observed. Our work demonstrates that the systemic availability or papaverine can be markedly affected by product formulation.